PSU IIL To Invest Rs 700 Cr On Greenfield Project In Hyderabad
Expectedly the facility would be a state-of-art fully integrated biosafety level 3 (BSL-3) to produce drug substance (DS) and respective fill-finish
Indian Immunologicals Limited (IIL) said that it will be investing Rs 700 crore for a greenfield animal vaccine manufacturing facility set-up in Genome Valley, Hyderabad, on 10 October. IIL is a public sector vaccine maker which is owned by National Dairy Development Board (NDDB).
The facility will be engaged in making Foot and Mouth disease (FMD) and other emerging diseases. The proposed facility will generate employment for nearly 750 people in total.
Expectedly the facility would be a state-of-art fully integrated biosafety level 3 (BSL-3) to produce drug substance (DS) and respective fill-finish.
Also, the said facility will add another 300 million doses for which the production would commence in the 3rd year after it is built.
Presently. IIL manufactures around 150 products and it is already world’s one of the largest manufacturers of FMD vaccine. Also, being a leading firm, it supplies FMD vaccine to the Government of India’s National Animal Disease Control Programme (NADCP).